27-May-22
22-Jun-21
Spot the difference. There's only 2 reasons they would remove FTO expression status as an endpoint:
1. They think Zantrene is validated as an FTO inhibitor.
2. The opposite.
Either way, doesn't look like they wanted to leave this to an investigator-led trial to report. I imagine they will want to announce this data (if validating) off the back of their own work, validated by Sheba.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
-0.030(2.42%) |
Mkt cap ! $210.2M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $76.28K | 63.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3248 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 8387 | 1 |
View Market Depth
| Last trade - 14.14pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |